A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia

A Phase II, MultiCenter, Double-Blind Study to Evaluate the Efficacy and Safety of SHR4640 and Febuxostat in Subjects With Hyperuricemia

The objective of the study is to assess the Safety and Efficacy of SHR4640 and Febuxostat in patients with Hyperuricemia.

Inclusion Criteria:

• Subject has a body mass index ≥18 and ≤30 kg/m2;
• Screening sUA value ≥8mg/dl;
• Subject has no clinically relevant abnormalities in vital signs, ECG, physical examination，imaging examination or safety laboratory values.

Exclusion Criteria:

• Subject known or suspected of being sensitive to the study drugs or its ingredient；
• ALT、AST、TBIL>1.5ULN;
• History of kidney stones or screening kidney stones by B-ultrasound；
• History of malignancy；
• History of xanthinuria；
• Donated blood（≥400ml）within 3 months prior to screening or received transfusion of blood.